ZSX 2nd Quarter 2011 Newsletter

Summer Greetings from ZSX Medical!

ZSX Medical is pleased to bring you the summer edition of our newsletter. In this edition, we’ll be discussing what we’ve been working on over the past few months. Our newsletter also includes a discussion of what makes the biomaterials area so attractive for medical device companies.

ZSX Medical Tackles Wound Closure in Hysterectomy

Early this quarter, ZSX Medical broadened its strategic approach, applying the Zip-Stitch™ technology to hysterectomy in addition to cesarean delivery. Together, they number about 2 million procedures in the U.S. annually. Now ZSX Medical is developing closure products to address the first and third most common large incision surgeries in America. As these procedures are exclusive to women, this expansion of the company’s product portfolio is consistent with our mission to reinvent surgical closure in women’s health.
The immediate benefits to pursuing hysterectomy are reduced time to market, a clearer regulatory pathway and gynecologists’ stated desire to improve minimally invasive closure in laparoscopic surgeries.

New Patent Filing for Zip-Stitch™

ZSX Medical has also recently filed a new patent application reflecting improvements in the Zip-Stitch™ design as well as hysterectomy-specific features. This new patent covers all of the advances that have been made in the development of the Zip-Stitch™ technology over the past year and will protect multiple generations of products in years to come.

Strategic Planning Meeting for Zip-Stitch™ in Hysterectomy
On the 6th of June, ZSX Medical convened a group of key scientific, clinical, and regulatory advisors to discuss issues related to the application of Zip-Stitch™ to hysterectomy. This meeting produced a road map for the development of Zip-Stitch™ in hysterectomy, which will guide ZSX Medical’s work over the next several months in this area.

ZSX Medical makes Headway in Pre-clinical Testing

ZSX is always conducting bench-top and animal studies to advance Zip-Stitch™. Since these studies are confidential, and the information learned from them needs to be kept secret, it’s difficult to say much about them in a newsletter, even though these studies are some of the most important work we’re doing. Since we can’t talk about the research itself, we’ll just take these sentences to highlight some of our key partners who have helped us in these studies. Two of the key bench top studies we conducted this quarter utilized resources and expertise from Widener University, in Chester, PA and Synectic Medical Products Development in Milford, CT. And one of our key animal studies was conducted in collaboration Synechion, Inc., in Dallas, TX.

Article of Interest: Advances in Biomaterials

Biomaterials can be loosely defined as materials that are compatible with being used in the human body. Biomaterials include natural materials, such as catgut (used to make some sutures), but also include synthetics, such as ultrahigh molecular weight polyethylene (used in some permanent hip implants). Biomaterials have applications from prostheses to tissue repair technologies to drug delivery systems and diagnostics. The global biomaterials market is currently estimated at $25 billion today, and is expected to reach $58 billion by 2014.1
One of the key challenges in this field is to develop suitable materials for medical implants, since the human body will react negatively to materials that are recognized as foreign substances. Biocompatibility issues are always a concern and much research is being conducted to develop biomaterials that elicit no or minimal immune or allergic response. Fortunately, there now exist a number of materials that are known to elicit minimal response when exposed to tissue for extended periods of time. Among these materials are degradable polymers. A polymer is a material that consists of long molecular chains made by stringing many smaller molecular units together. These polymers can break apart slowly in the body, making them degradable. By modifying the individual groups (monomers) and how they combine, we can control the way the material behaves and how quickly it degrades. What’s promising about new degradable polymers is that we already know how the body reacts to the monomers as they break down, so we can develop new polymers with less risk that the body will reject them.
Biomaterials made from degradable polymers have re-invigorated the market for wound closure with the development of bioabsorbable sutures, staplers, ligating clips, adhesives and surgical meshes.
ZSX Medical’s team includes renowned experts in material sciences and utilizes degradable polymers throughout our Zip-Stitch™ platform technology. ZSX Medical is employing the latest medical research to re-invent surgical closure in women’s health.

Keeping in Touch

ZSX Medical is reachable through www.ZSXMedical.com or www.ZipStitch.com

In addition to this newsletter, we may use our site periodically as a mechanism to keep interested parties informed as to our progress. Check back often!

Dan Mazzucco, President & CTO
Eric Rugart, COO

For more information regarding Zip-Stitch™, email us at info@zsxmedical.com. Click HERE for email updates